Home > Insider Trading > Filing (0001209191-18-056332)

Filing Details

Accession Number:: 0001209191-18-056332
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-10-26 18:43:58
Reporting Period:: 2018-10-24

Accepted Time:: 2018-10-26 18:43:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
873303	Sarepta Therapeutics Inc.	SRPT	Pharmaceutical Preparations (2834)	930797222

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1511034	Sandesh Mahatme	215 First Street, Suite 415 Cambridge MA 02142	Evp, Cfo & Cbo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-10-24	9,596	$23.85	48,381	No	4	M	Direct
Common Stock	Acquisiton	2018-10-24	39,006	$13.90	87,387	No	4	M	Direct
Common Stock	Acquisiton	2018-10-24	29,080	$13.71	116,467	No	4	M	Direct
Common Stock	Acquisiton	2018-10-24	11,718	$13.71	128,185	No	4	M	Direct
Common Stock	Disposition	2018-10-24	107,524	$127.74	20,661	No	4	S	Direct
Common Stock	Disposition	2018-10-24	12,012	$0.00	8,649	No	5	G	Direct
Common Stock	Acquisiton	2018-10-24	12,012	$0.00	12,012	No	5	G	Indirect	By wife

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	5	G	Direct
No	5	G	Indirect	By wife

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2018-10-24	9,596	$0.00	9,596	$23.85
Common Stock	Stock Option (right to buy)	Disposition	2018-10-24	39,006	$0.00	39,006	$13.90
Common Stock	Stock Option (right to buy)	Disposition	2018-10-24	29,080	$0.00	29,080	$13.71
Common Stock	Stock Option (right to buy)	Disposition	2018-10-24	11,718	$0.00	11,718	$13.71

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
116,009	2022-11-05	No	4	M	Direct
17,860	2025-02-27	No	4	M	Direct
7,899	2026-02-28	No	4	M	Direct
12,873	2026-02-28	No	4	M	Direct

Footnotes

These trades were made pursuant to a Rule 10b5-1 trading plan.
The shares were sold in multiple transactions at prices ranging from $120.87 to $134.39, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the range set forth herein.
This transaction involved a gift of securities by the reporting person to his wife.
The option to purchase shares is fully vested.
The option vests based on time criteria (25% of the total option on 2/27/2016 and 1/48th of the total option in equal monthly installments thereafter).
Half of the total options granted began vesting when the FDA provided marketing approval for eteplirsen on 9/19/2016 and the other half of the total options granted began vesting when Sarepta Therapeutics, Inc. filed a Marketing Authorization Application with the European Medicines Agency on 11/30/2016. Vesting of the options allocated to the achievement of each goal is as follows: (i) 50% of the options allocated to the achieved goal vested immediately upon achievement of the performance condition (25% of the total performance-based options granted) and (ii) the remaining 50% of the options allocated to the achieved goal (25% of the total performance-based options granted) vest over four years. 25% of the remaining options vested on the first year anniversary of the grant date, or 2/28/2017 and 1/48th of the remaining options vests monthly thereafter.
The option vests based on time criteria (25% of the total option on 2/29/2017 and 1/48th of the total option in equal monthly installments thereafter).